68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can
 show prostate cancer on a PET/CT scan. 68Ga-RM2 stands for Galium-68 labeled
 DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2. This study
 is being done because there are unmet medical needs to improve the current ways of detecting
 prostate cancers before surgery.
Inclusion Criteria:

 -  Age ≥18 years

 -  Biopsy proven adenocarcinoma of the prostate

 -  Patients with low-risk, intermediate-risk and high-risk tumors according to NCCN
 guidelines (2.2014) will be included

 -  Planned radical prostatectomy at MSKCC

 -  Multiparametric MRI of the pelvis (performed or planned) as routine care

 Exclusion Criteria:

 -  Patients meeting any of the following exclusion criteria will not be eligible for
 study entry:

 -  Hematologic

 -  Platelets <75K/mcL

 -  ANC <1.0 K/mcL

 -  Hepatic laboratory values

 -  Bilirubin >2.0 x ULN (institutional upper limits of normal)

 -  AST/ALT >2.5 x ULN

 -  Renal laboratory values

 o Creatinine > 2.0 x ULN

 -  Claustrophobia interfering with MRI and PET/CT imaging

 -  Prior pelvic radiation

 -  Prior androgen deprivation therapy

 -  Patients deemed not surgical candidates due to prohibitive co-morbidities